Parkinson's disease and noradrenergic system;Maladie de parkinson et système noradrénergique

Presse Medicale

Volumn 31, Issue 26, 2002, Pages 1240-1242

  Brefel Courbon, Christine ^a  

^a UNIVERSITÉ DE TOULOUSE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIPARKINSON AGENT; CLONIDINE; DOPAMINE RECEPTOR STIMULATING AGENT; EFAROXAN; IDAZOXAN; NEUROTOXIN; PIRIBEDIL; YOHIMBINE;

ANATOMY; ARTICLE; DYSKINESIA; HUMAN; NEUROTRANSMITTER RELEASE; NORADRENERGIC SYSTEM; PARKINSON DISEASE; PATHOPHYSIOLOGY;

EID: 0037055682     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Coexisting neurotranmitters in central noradrenergic neurons
2. Hippocampus norepinephrine, caudate dopamine and serotonin and behavioural responses to the stereoisomers of amphetamine and methamphetamine
3. Amphetamine paired with physical therapy accelerates motor recovery after stroke, Further evidence
4. Pharmacological manipulations of the α2-noradrenergic system, effects on cognition
5. α2 adrenoceptors and 12 sites in the mammalian central nervous system
6. The role of the locus cœruleus in the development of Parkinson's disease
7. Qualitative and quantitative analysis of locus cœruleus neurons in Parkinson's disease
8. Disease specific pattern of locus cœruleus cell loss
9. Brain noradrenaline and 3-methoxy-4hydroxyphenylglycol in Parkinson's syndrom
10. Parkinson's disease and dementia: Norepinephrine and dopamine in locus cœruleus
11. Alpha2-adrenoceptor antagonists: A new approach to Parkinson's disease
12. Effects of an alpha 2 antagonist in a 20-year-old java monkey with MPTP-induced parkinsonian signs
13. Effect of the alpha2 adrenoceptor antagonist, idazoxan, on motor disabilities in MPTP-treated monkey
14. The α2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-Dopa in the MPTP-lesioned primate model of Parkinson's disease
15. Noradrenoceptor antagonism with idazoxan improves L-dopa-induced dyskinesias in MPTP monkeys
16. Short term oral administration of idazoxan in mild stable parkinsonian patients treated with L-DOPA
17. Efficacy and safety to efaroxan, an α2 adrenoceptor antagonist, in Parkinson's disease: An oral short-term study
18. Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct: Evidence from the effects of the alpha adrenoceptor antagonist idazoxan
19. Effects of nondopaminergic drugs on L-Dopa-induced dyskinesias in MPTP-treated monkeys
20. Idazoxan, an alpha-2 antagonist, and L-Dopa-induced dyskinesias in patients with Parkinson's disease
21. Antiparkinsonian agent piribedil displays antagonist properties at native, rat, and cloned, human α2-adrenoceptors: Cellular and functional characterization
22. Piribedil induces low levels of dyskinesia in MPTP-treated common marmosets
23. The effects and after effects of the α2 adrenoceptor antagonist idazoxan on mood, memory and attention in normal volonteers
24. The α2 antagonist idazoxan remediates certain attentional and executive dysfunction in patients with dementia of frontal type
25. Attentional deficits in Parkinson's disease: Partial reversibility with naphtoxazine (SDZ NVI-085), a selective noradrenergic alpha 1 agonist
26. Le piribedil améliore la vigilance et la motricité chez le marmoset traité au MPTP plus que la L-dopa
27. Psychomotor and cognitive effects of piribedil, a dopamine agonist, in healthy young volunteers
28. Sleep attacks and Parkinson's disease treatment